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To examine the use of 2-deoxy-2-~sF]fluoro-D-glucose (ZFDG) as a glucose analog for measuring glucose 
utilization rate in myocardium, dual-tracer kinetic experiments with 2-FDG and 2-PHIglucose were per- 
formed in the perfused, isolated rabbit interventricular septum to measure simultaneously the transport and 
phosphorylation rates of glucose and 2-FDG. Results of the present study indicated that, in the septum, 
(i) the transport rate constants of 2-FDG and glucose were similar in magnitude, (ii) the phosphorylation 
rate constant for 2-FDG was about 60% of that of glucose, (iii) hypoxia caused an increase in phosphoryla- 
tion rates of glucose and 2-FDG without ieeting transport. 
2-PHIGlucose; 2-Deoxy-2-rsF]fluoro-D-glucose; Tracer kinetics; Glucose transport; Glucose phosphorylation; 
(Rabbit myocardium) 
1. INTRODUCTION 
2-Deoxy-2-[‘8F]fluoro-D-glucose (2-FDG), an 
analog of glucose, is used in positron emission 
tomography (PET) to measure regional glucose 
utilization rates in brain and myocardium [I ,2]. 
Therefore, it is imperative to characterize the 
behavior of 2-FDG relative to that of glucose 
under various physiological states in order to ac- 
curately interpret PET results. 
Transport and phosphorylation rates of natural 
glucose in myocardium have been obtained earlier 
Correspondence address: S.C. Huang, Division of 
Nuclear Medicine and Biophysics, Department of 
Radiological Sciences, UCLA, Los Angeles, CA 90024, 
USA 
[3], but differences in the experimental preparation 
and assumptions make it difficult to compare 
results with those obtained from 2-FDG 
measurements [4,5]. In this study, we have used 
2-[3H]glucose along with 2-FDG in dual-tracer 
kinetic experiments to simultaneously measure the 
transport and phosphorylation rates of glucose 
and 2-FDG in the perfused, isolated rabbit in- 
terventricular septum. Though with some limita- 
tions, the septum preparation was selected because 
it can provide relative transport and phosphoryla- 
tion rates of the two tracers while eliminating the 
technical difficulties associated with chamber 
blood volume in other heart preparations, viz., 
uncertainty about the contribution of chamber 
radioactivity to the kinetic measurements. The 
dual-tracer technique minimizes the inter-study 
variability and thus permits more accurate and sen- 
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sitive comparisons of the relative kinetic behaviors 
of the two tracers. 
2. MATERIALS AND METHODS 
2-FDG was synthesized by using a previously 
reported procedure [6]; 2-[3H]glucose (99% purity) 
was purchased from New England Nuclear. 
The isolated rabbit interventricular septum 
preparation was perfused by constant infusion at 
1 .O ml/min per g with a modified Tyrode solution 
(containing 5 mu/ml insulin), and paced at 72 
stimuli/min, at 37°C. Eleven experiments were 
performed under normoxia (condition A), in 
which the perfusate (9 mM HCO;) was aerated 
with 98% 02/2% CO2 and had a pH of 7.4. Eight 
experiments were conducted under hypoxia (condi- 
tion B), in which the perfusate (28 mM HCO:) 
was aerated with 47.5% G2/47.5% NJY70 COZ. 
enzymatic techniques described by Bergmeyer 171. 
Radio-labeled compounds were assayed by 
chromatography (anion-exchange resin AG l-X8, 
100-200 mesh formate form); eluted initially with 
water, followed by a formic acid gradient 
(O-l M), and a final formic acid to ammonium 
formate gradient (0.63-l M). The relative 
distribution of the tritium label among the assayed 
compounds in these selected samples was used to 
correct for the tritium activity in the effluent 
samples that was not 2-[3H]glucose. 
Freeze-clamped tissue samples were mechanical- 
ly pulverized and then extracted with 0.4 N per- 
chloric acid. An aliquot of the acid extracted tissue 
was neutralized and assayed for glucose, 
glucose-6-P, lactate and their radiolabeled 
counterparts, using analogous procedures to those 
described earlier for effluent samples. 
After reaching a steady state of mechanical 
function, the preparation was infused with an 
identical solution containing 2-FDG (2.0 &i/ml) 
and 2-[3H]glucose (0.5 &i/ml) for 90 min, during 
which time the r*F radioactivity in the septum, as 
a function of time, was measured by a coincidence 
counting probe system and recorded by a com- 
puter. Effluent samples were collected throughout 
the 90 min. Samples from the perfusate arterial 
source were obtained every 10 min. Freeze- 
clamped tissue samples (300 mg) were taken at the 
end of four experiments, two from condition A 
and two from B. 
The measured time activity data of 2-FDG and 
2-[‘HIglucose in the effluent were curve fitted us- 
ing a two-compartment model (fig. 1) to determine 
the transport and phosphorylation rates of 2-FDG 
and glucose. The value of the 2-FDG lumped con- 
stant (LC) [1,2,4,5,8] that accounts for the overall 
difference in transport and phosphorylation of 
2-FDG versus glucose was calculated as the ratio of 
Cpklk3/(k2 + k3) to the net glucose utilization that 
was measured by the use of Fick’s method [4]. 
3. RESULTS AND DISCUSSION 
The ‘*F radioactivity in the effluent and arterial 
samples were counted in a well counter. The up- 
take of “F by the septum as a function of time was 
calculated from the arterial-venous 2-FDG dif- 
ference. This indirectly derived uptake curve was 
compared with the time-activity curve measured 
directly from the septum with the coincidence 
counting system to establish a calibration factor 
between the two measurements. 
Table 1 shows perfusion flow, glucose utiliza- 
tion and lactate production of the septum. Under 
condition B, the developed tension was reduced, 
and both glucose utilization and lactate production 
were increased. The molar ratio of lactate produc- 
tion to glucose utilization in table 1 indicates that 
37% of the metabolized glucose is converted to lac- 
tate under condition A, while 73% is converted to 
lactate under condition B, consistent with the 
reduced oxygen supply in the perfusate. 
The collected arterial and effluent samples, after After and 
“F decay (tl/, = 
uptake phosphorylation of 
110 min) and removal of tritiated 2-[3H]glucose, that are identical to those of natural 
water by repeated evaporations, were analyzed for glucose, the tritium label on 2-[3H]glucose-6-P has 
tritium radioactivity by liquid scintillation coun- a high probability of being released as tritiated 
ting. Samples taken at 5, 15, 30, 45, 60 and 90 min water (t-water) in each cycle through the 
were assayed for glucose, glucose-6-P, lactate, 
2-[3H]glucose, 2-[3H]glucose-6-P and [3H]lactate 
phosphoglucose isomerization reaction [9]. If the 
isomerization rate is faster than the phosphofruc- 
concentrations. Concentrations of glucose, tokinase reaction, each 2-[3H]glucose-6-P molecule 
glucose-6-P, and lactate were determined by the would have multiple reversible passes through the 
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Table 1 
Group Flow Lactate Glucose L/Gb 
(ml/min production utilization 
per g) (umol/min (umol/min 
per 100 g) per 100 g) 
A (n = 11) 1.06 f 0.16a 17.0 + 4.2 23.0 + 4.3 0.74 
B (n = 8) 1.03 * 0.07 55.1 f 1.3 38.1 + 6.3 1.45 
= SD 
b Molar ratio of lactate production to glucose utilization (note that 1 mol 
of glucose produces 2 mol of lactate) 
May 1987 
isomerization reaction, and a majority of the 
tritium label will be lost as t-water. In this case, 
there will be no labeled compounds in tissue other 
than 2-[‘HIglucose, 2-[3H]glucose-6-P and t-water. 
However, the results of table 2 show that the la- 
beled lactate was also observed in tissue and ef- 
fluent. The specific activity of lactate relative to 
that of glucose indicates that only 80% of the 
tritium in 2-[3H]glucose-6-P was lost to t-water in 
the phosphoglucose isomerization reaction. ‘The 
amount of tritiated lactate (t-lactate) cleared from 
tissue was only about 7% (condition A) and 9% 
(condition B) of the total 2-[3H]glucose 
phosphorylated by hexokinase in tissue. The re- 
maining tritium label could be accounted for as 
pyruvate, entering the TCA cycle and eventually 
being converted to t-water. As expected, no labeled 
glucose-6-P was detected in the effluent samples, 
because of its inability to cross the cell membrane. 
The amount of t-lactate relative to total tritium 
radioactivity in effluent samples was found to be 
constant over time. 
The uptake and phosphorylation of 2-FDG in 
tissue are similar to those of glucose [ 1,8] and can 
be described by the compartmental model il- 
lustrated in fig.1 [4,5]. The rates of glucose 
transport and phosphorylation in tissue are 
reflected in the tracer kinetics of 2-[3H]glucose that 
are also describable by the same model (legend to 
fig.1). Table 3 shows the estimated rate constants 
of transport and phosphorylation of glucose and 
2-FDG. The ratios of ki and k2 between 2-FDG 
and glucose were very close to 1 .O under both con- 
ditions, indicating that the transport mechanism is 
not preferential toward glucose or 2-FDG. The 
value of k3 was higher under condition B reflecting 
a higher glucose consumption. However, the ratio 
of k3 between 2-FDG and glucose indicates that 
hexokinase is about 60% as efficient for 2-FDG as 
compared to glucose with no significant changes 
Table 2 
Tritium specific activities 
Tissue 
Effluent 
Group A (n = 2) Group B (n = 2) 
Glucose Lactate L/Ga Glucose Lactate L/Ga 
(&i/mmol) (.uCi/mmol) (uCi/mmol) (crCi/mmol) 
81.0 8.0 0.10 82.8 8.5 0.10 
77.1 10.6 0.14 76.0 8.7 0.11 
a Molar ratio of specific activities of lactate to glucose (note that 1 mol of glucose 
produces 2 mol of lactate) 
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Fig.1. A compartmental model for the transport and 
phosphorylation of 2-FDG in tissue. Cp denotes the 
2-FDG concentration in perfusate; Cu is the free 2-FDG 
concentration in tissue; CM is the 2-FDG-6-P con- 
centration in tissue. kl and k2 denote the forward and 
backward transport rate constants; ks and k4 are the rate 
constants of the phosphorylation and dephosphoryla- 
tion reactions. The same model is applicable for 2-[3H]- 
glucose, except the value of k4 is zero for 2-[3H]glucose 
because of the loss of tritium label from 
2-[3H]glucose-6-P to t-water in the phosphoglucose 
isomerization reaction. 
between conditions A and B (52.8% for condition 
A vs 63.2% for condition B). The measured values 
of LC were 0.56 and 0.63, respectively, for condi- 
tions A and B. The difference was not statistically 
significant 0, > 0.05). 
The present study shows the viability of the 
dual-tracer technique using 2-FDG and 2-13H]- 
glucose for characterizing the behavior of 2-FDG 
as a glucose analog in myocardium. Moreover, the 
results show the production of t-water from 
2-[3H]glucose is not necessarily an accurate in- 
dicator of glucose utilization as is commonly used, 
unless the presence of other possible metabolites 
(e.g., t-lactate) is considered. 
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Table 3 
Group kr kz ks k4 Vda LCb 
(ml/min per g) (min) (min) (min) (ml/g) 
2-FDG 0.348 0.553 0.041 0.010 0.59 0.56 
(o.079)c (0.111) (0.014) (0.007) (0.10) (0.12) 
A 2tGlcd 0.326 0.517 0.077 - 0.55 
(0.077) (0.084) (0.019) - (0.10) (Z) 
Ratio’ 1.083 1.082 0.528 - 1.08 0.57 
(0.172) (0.211) (0.092) - (0.06) (0.11) 
2-FDG 0.361 0.545 0.073 0.61 0.63 
(0.088) (0.184) (0.020) (KZ) (0.12) (0.10) 
B 2tGlc 0.368 0.589 0.116 - 0.56 0.94 
(0.087) (0.249) (0.015) - (0.12) (0.08) 
Ratio 1.008 1.017 0.632 - 1.09 0.67 
(0.206) (0.299) (0.177) - (0.12) (0.12) 
a Vd = kl/(kz + k3) is the apparent distribution volume of the tracer in tissue 
b LC, lumped constant, denoting the ratio of Cpklk3/(k2 + k3) to net glucose utilization rate (by 
Fick’s method) 
’ Values in parentheses denote SD 
d 2tGlc: 2-13H]glucose 
e Ratio of 2-FDG value to 2tGlc value 
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